REGENXBIO INC (RGNX) Stock Fundamental Analysis

NASDAQ:RGNX • US75901B1070

8.08 USD
+0.14 (+1.76%)
Last: Feb 24, 2026, 01:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RGNX. RGNX was compared to 521 industry peers in the Biotechnology industry. RGNX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RGNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • RGNX had negative earnings in the past year.
  • RGNX had a negative operating cash flow in the past year.
  • RGNX had negative earnings in 4 of the past 5 years.
  • RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -33.88%, RGNX is in the better half of the industry, outperforming 63.15% of the companies in the same industry.
  • RGNX has a Return On Equity of -110.20%. This is comparable to the rest of the industry: RGNX outperforms 42.61% of its industry peers.
Industry RankSector Rank
ROA -33.88%
ROE -110.2%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • RGNX has a Gross Margin of 87.18%. This is amongst the best in the industry. RGNX outperforms 89.64% of its industry peers.
  • RGNX's Gross Margin has declined in the last couple of years.
  • RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RGNX has been increased compared to 1 year ago.
  • The number of shares outstanding for RGNX has been increased compared to 5 years ago.
  • The debt/assets ratio for RGNX has been reduced compared to a year ago.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • RGNX has an Altman-Z score of -2.35. This is a bad value and indicates that RGNX is not financially healthy and even has some risk of bankruptcy.
  • RGNX has a Altman-Z score (-2.35) which is comparable to the rest of the industry.
  • RGNX has a Debt/Equity ratio of 0.93. This is a neutral value indicating RGNX is somewhat dependend on debt financing.
  • RGNX has a Debt to Equity ratio of 0.93. This is in the lower half of the industry: RGNX underperforms 74.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Altman-Z -2.35
ROIC/WACCN/A
WACC8.27%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • RGNX has a Current Ratio of 2.66. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RGNX (2.66) is worse than 69.48% of its industry peers.
  • RGNX has a Quick Ratio of 2.66. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
  • RGNX's Quick ratio of 2.66 is on the low side compared to the rest of the industry. RGNX is outperformed by 67.56% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.32% over the past year.
  • The Revenue has grown by 91.30% in the past year. This is a very strong growth!
  • The Revenue has been growing by 18.81% on average over the past years. This is quite good.
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%

3.2 Future

  • RGNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.30% yearly.
  • Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 49.03% on average per year.
EPS Next Y30.27%
EPS Next 2Y19.99%
EPS Next 3Y12.93%
EPS Next 5Y16.3%
Revenue Next Year105.19%
Revenue Next 2Y71.01%
Revenue Next 3Y55.97%
Revenue Next 5Y49.03%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
  • Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • RGNX's earnings are expected to grow with 12.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.99%
EPS Next 3Y12.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REGENXBIO INC

NASDAQ:RGNX (2/24/2026, 1:07:54 PM)

8.08

+0.14 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners83.17%
Inst Owner Change-1.03%
Ins Owners7.13%
Ins Owner Change15.4%
Market Cap409.01M
Revenue(TTM)161.32M
Net Income(TTM)-177.91M
Analysts84.21
Price Target33.35 (312.75%)
Short Float %10.56%
Short Ratio5.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.56%
Min EPS beat(2)-22.99%
Max EPS beat(2)9.88%
EPS beat(4)2
Avg EPS beat(4)-18.77%
Min EPS beat(4)-75.63%
Max EPS beat(4)13.65%
EPS beat(8)3
Avg EPS beat(8)-8.87%
EPS beat(12)5
Avg EPS beat(12)-7.23%
EPS beat(16)6
Avg EPS beat(16)-6.26%
Revenue beat(2)1
Avg Revenue beat(2)-2.34%
Min Revenue beat(2)-25.51%
Max Revenue beat(2)20.83%
Revenue beat(4)1
Avg Revenue beat(4)-7.89%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)20.83%
Revenue beat(8)2
Avg Revenue beat(8)-13.33%
Revenue beat(12)3
Avg Revenue beat(12)-16.53%
Revenue beat(16)5
Avg Revenue beat(16)-11.02%
PT rev (1m)-0.23%
PT rev (3m)3.91%
EPS NQ rev (1m)1.97%
EPS NQ rev (3m)-1.42%
EPS NY rev (1m)-3.32%
EPS NY rev (3m)-23.06%
Revenue NQ rev (1m)-7.77%
Revenue NQ rev (3m)-12.81%
Revenue NY rev (1m)-2.44%
Revenue NY rev (3m)-23.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.54
P/FCF N/A
P/OCF N/A
P/B 2.53
P/tB 2.53
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-2.56
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS3.19
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.88%
ROE -110.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.18%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.93%
Cap/Sales 1.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -2.35
F-Score4
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
EPS Next Y30.27%
EPS Next 2Y19.99%
EPS Next 3Y12.93%
EPS Next 5Y16.3%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%
Revenue Next Year105.19%
Revenue Next 2Y71.01%
Revenue Next 3Y55.97%
Revenue Next 5Y49.03%
EBIT growth 1Y36.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.09%
EBIT Next 3Y23.42%
EBIT Next 5Y19.27%
FCF growth 1Y54.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.4%
OCF growth 3YN/A
OCF growth 5YN/A

REGENXBIO INC / RGNX FAQ

What is the ChartMill fundamental rating of REGENXBIO INC (RGNX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RGNX.


What is the valuation status for RGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to REGENXBIO INC (RGNX). This can be considered as Overvalued.


Can you provide the profitability details for REGENXBIO INC?

REGENXBIO INC (RGNX) has a profitability rating of 2 / 10.


What is the financial health of REGENXBIO INC (RGNX) stock?

The financial health rating of REGENXBIO INC (RGNX) is 3 / 10.